Body / AbdominalAI / InformaticsResearch

AI-aided ascites volume measurement predicts survival in HCC patients on atezolizumab/bevacizumab

Cancer imaging : the official publication of the International Cancer Imaging Society3d ago

In HCC patients on atezolizumab/bevacizumab, AI-assisted CT volumetry showed high-volume ascites (≥613.5 mL) independently predicted worse overall survival (HR 4.01, p<0.001), while low-volume ascites did not.

  • Retrospective study of 90 HCC patients on atezolizumab/bevacizumab; ascites present in 39% (median volume 344 mL, IQR 29-929).
  • Ascites volume as a continuous variable associated with worse OS on univariate analysis (HR 2.88, p<0.001) but not after multivariate adjustment.
  • High-volume ascites (≥613.5 mL) was independently associated with impaired OS (HR 4.01, p<0.001), whereas low-volume ascites was not.
Read the source

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.